Search hospitals > Washington > Tacoma
Northwest Medical Specialties PLLC
Claim this profileTacoma, Washington 98405
Global Leader in Parotid Gland Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
310 reported clinical trials
10 medical researchers
Summary
Northwest Medical Specialties PLLC is a medical facility located in Tacoma, Washington. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Lung Cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Northwest Medical Specialties PLLC is involved with conducting 310 clinical trials across 421 conditions. There are 10 research doctors associated with this hospital, such as Richard L. Deming, Li Zhang, MD, Sibel Blau, and Jorge Chaves, MD.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Richard L. DemingMercy Medical Center - Des Moines6 years of reported clinical research
Expert in Parotid Gland Cancer
Expert in Cancer
178 reported clinical trials
242 drugs studied
Li Zhang, MDSun Yat-sen University Cancer Center2 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
22 reported clinical trials
28 drugs studied
Sibel BlauNorthwest Medical Specialties1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
12 reported clinical trials
24 drugs studied
Jorge Chaves, MDNorthwest Medical Specialties8 years of reported clinical research
Studies Cancer
Studies Melanoma
9 reported clinical trials
26 drugs studied
Clinical Trials running at Northwest Medical Specialties PLLC
Breast Cancer
Lung Cancer
Cancer
Bladder Cancer
Multiple Myeloma
Breast cancer
Bladder Carcinoma
Parotid Gland Cancer
Non-Small Cell Lung Cancer
Testicular cancer
Elacestrant
for Breast Cancer
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Recruiting2 awards Phase 33 criteria
sac-TMT + Pembrolizumab
for Breast Cancer
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.
Recruiting2 awards Phase 35 criteria
Sacituzumab Tirumotecan
for Breast Cancer
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone. Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy: * Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy * Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy
Recruiting2 awards Phase 36 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Northwest Medical Specialties PLLC?
Where is Northwest Medical Specialties PLLC located?
Who should I call to ask about financial aid or insurance network?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.